Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Futures: FTSE +0.03%, DAX (0.20%), CAC +0.23%

Aug 14 ,2025

  • Synopsis

    • European equity markets are set to open mixed with Asian equities trading also mixed Thursday. Nikkei pulling back from record high with losses also picking up in Korea and Taiwan. Hang Seng erased initial gains with Tencent off best levels. Financials driving rebound in Australia following latest bank earnings. Taiwan and Korea little changed. S&P 500 futures touch lower afterhours. Front-end JGB yields moving higher alongside yen after Bessent voiced expectation of BOJ rate hike. Treasuries little changed. Dollar muted outside yen cross. Crude edging higher while gold flat. Bitcoin extended gains to new record high.

    • On today's agenda, in central banks, Norges Bank interest rate decision announced at 10:00CET, with no change expected in the 4.25% benchmark interest rate. The decision on the countercyclical capital buffer rate will be published at the same time. Governor Ida Wolden Bache speaks at 10:30 at Arendal Week

    • Macroeconomic updates include: France Jul final CPI, UK Q2 preliminary GDP, Jul house price balance - RICS, Jun construction output, Eurozone Jun industrial production, Q2 GDP (2nd estimate), Switzerland Jul PPI, Sweden Jul final CPI, Finland Jul final CPI

    • In corporate news, a busy morning for earnings kicked off the session with DACHs region companies including - ThyssenKrupp (TKA.GR), Wacker Neuson (WAC.GR), RWE (RWE.GR), Bilfinger (GBF.GR), Swiss Re (SREN.SW) , Swissquote Group Holding (SQN.SW) - reporting their most recent earnings. Out of the Nordics, Embracer Group (EMBRAC.B.SS) reported Q1 adj. EPS (SEK0.69) vs FactSet SEK0.66 and now sees FY adj. EBIT of at least SEK 1.0B vs FactSet SEK 2.37B. Still in the Nordics, H. Lundbeck (HLUN.B.DC) increased its FY 2025 adjusted EBITDA growth guidance yesterday after the close. Zealand Pharma (ZEAL.DC) released Q2 numbers and confirmed its FY guidance. In the UK, Aviva (AV.LN), Antofagasta (ANTO.LN), Admiral Group (ADM.LN), are expected to update the market with their latest earnings.

  • Politics/Macro/World News

    • EU leaders sound upbeat after Ukraine call with Trump. They could be in for a rude awakening. - Politico

    • French borrowing costs close in on Italy's as investors fret over debts - FT

    • UK Jul house price balance (13%) vs consensus (5%) and prior (7%); sales market remains challenging as previous recovery signs falter- RICS

    • Finland Jul CPI +0.2% y/y vs consensus +0.4% and prior +0.2%

  • Top company news

    • Earnings/updates

      • DACHs

        • HFG.GR (HelloFresh) -- guides FY25 EBIT €175M and €225M vs prior guidance €200M and €250M

        • LXS.GR (Lanxess) -- reports Q2 net income (€45M) vs FactSet (€45.5M) [2 est, (€66)-(25M)]; cuts FY25 EBITDA guidance and announces further optimization of global production network

        • FHZN.SW (Flughafen Zuerich) -- reports July traffic statistics

        • AERO.SW (Montana Aerospace) -- reports H1 adjusted EBITDA €101.4M vs FactSet €95.5M [1 est]

        • HTG.GR (HomeToGo) -- reports Q2 adjusted EBITDA €7.4M +240.6% y/y

        • WAC.GR (Wacker Neuson) -- reports H1 EPS €0.42 vs year-ago €0.80; FY guidance confirmed

        • TKA.GR (ThyssenKrupp) reports Q3 EPS (€0.45) vs FactSet €0.20 [3 est, €0.15-0.23]; lowers FY sales growth guidance

        • GBF.GR (Bilfinger) -- reports Q2 EPS €1.28 vs FactSet €1.32 [2 est, €1.31-1.32]; confirms its FY25 outlook

        • SQN.SW (Swissquote Group Holding) -- reports H1 net income CHF158.2M vs FactSet CHF173.3M [2 est, CHF168-178.6M]; FY guidance revised upwards

        • SREN.SW (Swiss Re) reports Q2 net income $1.33B vs consensus $1.20B; maintains FY25 financial targets

        • RWE.GR (RWE) -- reports H1 adj net income €775M vs consensus €819M; confirms its FY25 outlook

        • HLAG.GR (Hapag-Lloyd) -- reports Q2 EPS €1.47 vs FactSet €0.79 [2 est, €0.51-1.07]; earnings forecast for the 2025 financial year refined

      • Nordics

        • HLUN.B.DC (H. Lundbeck) -- increases FY 2025 adjustd EBITDA growth guidance to +16-21% from prior +8-14%

        • ZEAL.DC (Zealand Pharma) -- reports Q2 EPS DKK105.61 vs FactSet DKK109.33 [8 est, DKK96.35-123.86]; confirms FY guidance

        • AUTO.NO (AutoStore Holdings) -- reports Q2 net income $11.3M vs FactSet $1.6M [5 est, ($5)-7M]

        • FING.B.SS (Fingerprint Cards) -- reports Q2 EPS SEK0.00 vs year-ago (SEK0.01); on a clear path toward positive EBITDA

        • KESKOB.FH (Kesko) -- reports July sales from continuing operations €1.05B, +5.4% in comparable terms

        • VEI.NO (Veidekke) -- reports Q2 EPS NOK2.90 vs FactSet NOK2.84 [5 est, NOK2.71-3.00]

        • MORG.NO (Sparebanken Møre) -- reports Q2 EPS NOK2.26 vs FactSet NOK2.23 [5 est, NOK2.15-2.37]

        • NEWA.B.SS (New Wave Group) -- reports Q2 EPS SEK1.26 vs FactSet SEK1.60 [4 est, SEK1.47-1.79]

        • EMBRAC.B.SS (Embracer Group) -- reports Q1 adj. EPS (SEK0.69) vs FactSet SEK0.66 [6 est, SEK0.18-1.18]; now sees FY adj. EBIT of at least SEK 1.0B vs FactSet SEK 2.37B

        • HOLM.B.SS (Holmen) -- reports Q2 EPS SEK3.80 vs StreetAccount SEK4.34

      • Benelux

        • SHUR.BB (Shurgard Self Storage) -- reports Q2 adjusted EPRA earnings per share €0.46 vs year-ago €0.45

        • ADYEN.NA (Adyen) -- reports H1 net income €481.0M vs FactSet €492.2M [9 est, €459-518.1M]

    • M&A

      • EDP.PL (EDP-Energias de Portugal) -- completes disposal of two hydro power plants in Brazil (post EU close 13-Aug)

      • CNA.LN (Centrica) -- and Energy Capital Partners in exclusive talks to acquire National Grid Grain terminal in deal valued at ~£1.5B - FT

      • EDPR.PL (EDP Renovaveis) -- agrees to sell a 207 MWac (248 MWdc) solar portfolio in Italy to Encavis for an EV above ~ €0.25B (post EU close 13-Aug)

    • Healthcare

      • SAN.FP (Sanofi) -- Sanofi's rilzabrutinib receives orphan designation in the EU for IgG4-related disease

      • PRTC.LN (PureTech Health) -- founded entity Vedanta Biosciences announces Phase 2 study of VE202 in ulcerative colitis did not meet primary endpoint

      • BSLN.SW (Basilea Pharmaceutica Ltd) -- Basilea Pharmaceutica Ltd, Allschwil enters into exclusive license agreement with Venatorx Pharmaceuticals, Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil

    • Other

      • UBSG.SW (UBS Group) -- UBS on track to miss internal target to reduce workforce by 85K by the time Credit Suisse integration is complete - FT

      • HFG.GR (HelloFresh) -- increases share buyback program by up to €100M to a total of €175M

  • Key rating changes

    • Downgrades

      • BBY.LN (Balfour Beatty) -- to hold from buy at Investec

  • Data

    • Nikkei (1.27%) to 42724.57

    • Hang Seng (0.36%) to 25520.92

    • Shanghai Composite (0.22%) to 3675.52

    • S&P futures (5.5) vs prior close of 6488.8

    • €-$ (0.0001) or (0.01%) to 1.1705

    • $-¥ (0.97) or (0.66%) to 146.42

    • €-¥ (1.17) or (0.68%) to 171.36

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE